Sugammadex
- Generic Name
- Sugammadex
- Brand Names
- Bridion, Sugammadex Adroiq, Sugammadex Amomed, Sugammadex Fresenius Kabi, Sugammadex Mylan, Sugammadex Piramal
- Drug Type
- Small Molecule
- Chemical Formula
- C72H112O48S8
- CAS Number
- 343306-71-8
- Unique Ingredient Identifier
- 361LPM2T56
- Background
Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general anesthesia, ventilation, or tracheal intuba...
- Indication
Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide in adults and pediatric patients ≥2 years old who are undergoing surgery.
- Associated Conditions
- Neuromuscular blockade caused by vecuronium bromide
- Associated Therapies
- -
A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part A: Japanese Participants (P05956)
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT00591409
A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Japanese Participants. Part A (P05957)
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT00591786
Sugammadex After Continuous Infusion of Rocuronium During Sevoflurane and Propofol Anesthesia (P05949; MK-8616-028)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 52
- Registration Number
- NCT00559468
A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part B: Caucasian Participants (P05971)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-11-02
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT00552617
A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Caucasian Participants. Part B (P05974)
- First Posted Date
- 2007-11-02
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 102
- Registration Number
- NCT00552929
Dose-Finding Trial With Sugammadex Administered at 3 and 15 Minutes After 1.0 and 1.2 mg/kg Rocuronium Bromide in Participants of ASA Class 1-3 (P05944; MK-8616-024)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2019-02-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 174
- Registration Number
- NCT00535743
Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698)
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2015-03-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 91
- Registration Number
- NCT00535496
Efficacy, Pharmacokinetics and Safety of Org 25969 in Subjects With Normal or Impaired Renal Function (19.4.304)(P05948)(COMPLETED)
- First Posted Date
- 2007-06-05
- Last Posted Date
- 2017-06-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 30
- Registration Number
- NCT00482599
Safety and Efficacy of Sugammadex (Org 25969, MK-8616) in Participants With or Having a Past History of Pulmonary Disease (19.4.308) (P05932) (MK-8616-017)
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 86
- Registration Number
- NCT00475215
Comparison of the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616; Org 25969) in Elderly Participants With Adult Participants (MK-8616-029)
- First Posted Date
- 2007-05-17
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 162
- Registration Number
- NCT00474617
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath